Study results suggest improved efficacy of DMT therapy with SSRIs
Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company’s native DMT – in patients with Major Depressive Disorder (MDD).
The company highlights that a marked improvement was observed between the antidepressant effect of SPL026 treatment in the SSRI Cohort compared to the Non-SSRI Cohort – suggesting a potentially enhanced efficacy effect when SPL026 is administered in combination with SSRIs.
Dr Carol Routledge, Chief Medical and Scientific Officer of Small Pharma, stated: “Our primary goal in conducting this Phase 2b study was to understand if SPL026 could be safely administered in conjunction with SSRIs to assess whether patients would need to be withdrawn from their SSRI medication in future trials.
“While we were very pleased that the study demonstrated that patients may not need to be withdrawn, we were not expecting to see such a marked difference in efficacy when administering SPL026 in combination with SSRIs compared to SPL026 alone.”READ MORE